Skip to main content
. Author manuscript; available in PMC: 2016 Jan 27.
Published in final edited form as: Sci Signal. 2015 Jan 27;8(361):ra9. doi: 10.1126/scisignal.2005607

Fig. 1. A requirement for FADD in Kras-driven lung cancer.

Fig. 1

(A) Genetic strategy used to activate KrasLSL-G12D, Rosa26LSL-Luciferase and deplete Fadd:GFP expression in a lung-specific manner. (B) Representative bioluminescent images of KLuc, and KFLuc mice at 7 to 22 weeks after intranasal AdCre administration. (C) Average bioluminescence in Luc (n=7), FLuc (n=7), KLuc (n=25), and KFLuc (n=34) mice at specified times. (D) Representative images of CT scans of lungs from Luc, FLuc, KLuc, and KFLuc animals at shown times, with H&E slide corresponding to that animal from week 18 or week 22 as indicated. Arrows, lesions. H, heart. (E) Tumor and vascular volumes in KLuc (n=10) and KFLuc (n=17) mice analyzed by CT at indicated times. Data are means ± SEM. *P=0.009, **P=0.018, unpaired Student’s t-tests. (F) Co-localization of bioluminescence imaging and CT imaging for lung tumors in Luc, KFLuc and KLuc mice. Inset, H&E of lesion in KLuc mouse. (G) Survival plot of KLuc (n=19) and KFLuc (n=15) mice. Median survival time: KFLuc mice, 51.4 weeks; KLuc mice, 34 weeks. ***P=0.005, Wilcoxon log-rank test (95% CI).